Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032865 | 0.99 | GLP1R (0.61) | GLP1RCAPN1CTSKCTSSBCHE | |
| SCHEMBL25835366 | 0.96 | GLP1R (0.55) | GLP1RCAPN1CTSKCTSSBCHE | |
| SCHEMBL26032519 | 0.96 | GLP1R (0.55) | GLP1RCAPN1CTSKCTSSBCHE | |
| SCHEMBL26032874 | 0.93 | GLP1R (0.55) | GLP1RCAPN1CTSKCTSSLPAR1 | |
| SCHEMBL16853275 | 0.92 | GLP1R (0.58) | GLP1RCAPN1CTSKCTSSSIRT2 | |
| SCHEMBL20341078 | 0.92 | GLP1R (0.58) | GLP1RCAPN1CTSKCTSSSIRT2 | |
| SCHEMBL25835480 | 0.91 | CTSK (0.52) | GLP1RCAPN1CTSKCTSSBCHE | |
| SCHEMBL23475912 | 0.90 | GLP1R (0.56) | GLP1RCAPN1CTSKCTSSSIRT2 | |
| SCHEMBL16853476 | 0.90 | GLP1R (0.56) | GLP1RCAPN1CTSKCTSSSIRT2 | |
| SCHEMBL23475929 | 0.90 | GLP1R (0.56) | GLP1RCAPN1CTSKCTSSSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | GLP1R 1985/4885CAPN1 3157/4885CTSK 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.